Effect of Blood Gel Derivatives on Wound Healing in Mouse Injured Tissue Models.

Several previous studies in the field of assisted reproduction have focused on the use of blood gel derivatives, such as platelet-rich fibrin (PRF), as a treatment for endometrial rehabilitation. However, the ability to release growth factors and the gel form of this product led to the evolution of platelet lysates. In this study, blood gel derivatives, including PRF lysate, which was in liquid form, and PRF gel, were collected and evaluated for growth factors. It was shown to be effective in endometrial wound healing and regeneration in mouse injured uterine tissue models through structure and function (pinopode expression, embryo implantation) evaluation. The results demonstrated that the concentrations of growth factors, including PDGF-AB and VEGF-A, were higher in the PRF lysate compared to the PRF gel (p < 0.05). PRF lysate could release these growth factors for 8 days. Furthermore, both PRF gel and PRF lysate restored the morphology of injured endometrial tissues in terms of luminal and glandular epithelia, as well as uterine gland secretory activity. However, the presence of pinopodes and embryonic implantation were only observed in the PRF lysate group. It can be concluded that PRF lysate promotes wound healing in mouse injured tissue models in vitro, which can act as healing products in tissue repair.

Alginate-gelatin hydrogel supplemented with platelet concentrates can be used as bioinks for scaffold printing.

Background: Owing to the growing global demand for organ replacement and tissue regeneration, three-dimensional (3D) printing is widely recognized as an essential technology in tissue engineering. Biomaterials become a potential source of raw materials for printing ink by containing factors that promote tissue regeneration. Platelet concentrates are autologous biological products that are capable of doing that. Objectives: This study was carried out to create bioinks capable of providing biological signals by combining gelatin-alginate with platelet concentrates. Methods: This study combined platelet concentrates, including platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), with gelatin and alginate to create bioinks. Bioink properties, including gelatinization and pH, were assessed before printing. After that, the scaffolds were done, and the growth factor (GF) release and cytotoxicity from these scaffolds were performed. Results: Results showed that all the three bioinks, including alginate-gelatin (AG), alginate-gelatin-PRP (AGP), and alginate-gelatin-PRF (AGF) were gelatinized right at the end of bioink fabrication and had a pH around 7. The scaffolds from bioinks supplemented with platelet concentrates secreted GFs that remained for 12 d, and the extracts from them were not cytotoxic for the L929 cell line. Conclusion: In summary, bioinks were made by combining AG with platelet concentrates and had properties suitable for creating scaffolds with cell-oriented grafts in the development of artificial tissues and organs.

Self Nanoelmusifying Drug Delivery of Rosuvastatin: Bioavailability evaluation and in vitro - in vivo correlation.

BACKGROUND: Rosuvastatin, most commonly used in the form of calcium salt, belongs to the statin groups of synthetic antihyperlipidemic agents. Rosuvastatin possesses high permeability, however, its aqueous solubility is poor, causing a slow dissolution rate in water. Consequently, this dissolution rate has a decisive role in the release and absorption of rosuvastatin in the gastrointestinal tube. OBJECTIVE: The aims of this study were to evaluate the absorption of the drug from the self-nano emulsifying drug delivery system of rosuvastatin (Ros SNEDDS) compared to rosuvastatin substance and to develop a level-A in vitro-in vivo correlation (IVIVC) for Ros SNEDDS. METHOD: An in-house developed LC-MS/MS method was used to determine the concentrations of rosuvastatin in dog plasma. Six beagle dogs received an intravenous dose, Ros SNEDDS, rosuvastatin substance. In vitro dissolution of the Ros SNEDDS was carried out with different conditions. Correlation models were developed from the dissolution and absorption results of Ros SNEDDS. RESULTS: The results showed a 1.7-fold enhanced oral bioavailability and 2.1-time increase of rosuvastatin Cmax in Ros SNEDDS form, compared to the rosuvastatin substance. A 900 ml dissolution medium of pH of 6.6 has demonstrated its suitability, the in vitro dissolution model was studied and supported by the Weibull equation with a weighting factor of 1/y2 as it presented the lowest values of AIC. CONCLUSION: Ros SNEDDS demonstrated higher bioavailability of rosuvastatin in comparison to rosuvastatin substance and established a level A IVIVC used in future bioequivalence trials.